Everfront Biotech Holding Company Limited - Brain Cancer Clinical Programs and Research Pipelines
Everfront Biotech will participate in BIO ASIA–Taiwan 2023, the largest biotechnology industry event in Asia, from July 27 to July 30, 2023. This international biotech extravaganza is not to be missed. We are delighted to announce that our booth (NSTC INNO ZONE, 4F, N814) has been selected in the Nangang Exhibition Hall. We will showcase our recent achievements in new drug development. We look forward to your visit and participation.
Cerebraca® Wafer for the Treatment of Recurrent Malignant Brain Tumors Resistant to Standard Therapy | Hualien Tzu Chi Hospital
Cerebraca® wafer is an invention specifically designed for the treatment of recurrent malignant brain tumors that have shown resistance to standard therapies. It is a biodegradable polymer containing (Z)-BP. The main therapeutic mechanisms of Cerebraca wafer include: targeting and eradicating brain tumor stem cells, promoting necrosis, inhibiting proliferation, and suppressing tumor invasion and metastasis. Additionally, it can reduce the activity of MGMT and PD-L1 in malignant brain tumors, thereby enhancing the effectiveness of treatment for recurrent malignant brain tumors.
Cerebraca® Wafer has achieved significant progress in Phase I clinical trials for the treatment of malignant brain tumors, and has been invited to speak at the Asian Congress of Neurological Surgeons (ACNS).
Hualien Tzu Chi Hospital collaborated with the neurosurgery team from Tri-Service General Hospital to conduct clinical trials for the development of a new drug, Cerebraca® Wafer, for the treatment of malignant brain tumors, under the leadership of the Superintendent, Dr. Shinn-Zon. Dr. Lin was invited by the President of the Asian Congress of Neurological Surgeons, Professor Yoko Kato, to share the results of the phase I clinical trial via video conference on June 8th at 8:30 PM.
Our Team Is Honored with the National Innovation Award – Clinical Innovation for Treating Recurrent Malignant Brain Tumors
Everfront Biotech is a pharmaceutical company dedicated to the development of drugs for rare diseases. Cerebraca® Wafer is produced through a sterile process by combining a small molecule targeted anticancer drug with biomedical materials. It enables controlled release of the drug into the surrounding brain tissue, effectively killing tumor cells that cannot be removed by surgery and inhibiting drug resistance to frontline chemotherapy. Animal studies have shown an average survival extension of 2.5 times compared to current medications.
Preventing Recurrence of Malignant Brain Tumors: Hualien Tzu Chi Hospital's Research and Technology Transfer Benefit Patients
Breakthrough in Malignant Brain Tumor Treatment: Hualien Tzu Chi Hospital has transferred its technology to Everfront Biotech, which has developed a traditional Chinese medicine patch containing chemically synthesized components of Chinese Angelica (Danggui). This patch successfully inhibits tumor growth. Dr. Shinn-Zong Lin, Superintendent of Hualien Tzu Chi Hospital, explains, “During surgery, when there are remaining cells, we use the Chinese Angelica patch, and apply it directly to the surface of the brain after the surgery.” In the case of Stage IV malignant brain tumors, which have a high recurrence rate and an average lifespan of four months, mouse experiments have shown an additional 26 days of survival compared to traditional medications. The patch can inhibit cancer cell proliferation, induce apoptosis, and has the potential for future development as a targeted therapy or oral medication for market release.
A Glimmer of Hope in Brain Cancer Treatment
Cancer Prevention Summit: Focusing on Brain Cancer Patients. When it comes to malignant brain tumors, patients face an average survival time of only four months after recurrence. However, Hualien Tzu Chi Hospital has developed a groundbreaking technology using a component found in the Chinese herbal medicine, Chinese Angelica (Danggui), that can effectively kill brain cancer cells. By synthesizing this component with Western medication, the hospital has entered the clinical trial stage, aiming to bring new hope and possibilities to patients.
CTi News - Targeted Therapy for Malignant Brain Tumors
Hualien Tzu Chi Hospital and a pharmaceutical company have signed a cooperation agreement on the development of a new targeted therapy for brain tumors. The therapy will undergo clinical trials in three phases, a process expected to take at least five years to complete. Currently, two patients have registered for the trials, and there is hope that this targeted therapy will truly assist patients in combating malignant tumors.
Breakthrough in Malignant Brain Tumor Treatment! New Drug to Enter Human Trials
Hualien Tzu Chi Hospital announced today the development of a new drug for the treatment of malignant brain tumors. Following the successful completion of drug safety evaluations by the USFDA, the drug is set to enter human trials, with the potential to reduce the recurrence rate of malignant brain tumors. In addition, under the leadership of Dr. Shinn-Zong Lin, Hualien Tzu Chi Hospital has also published a series of cell therapy and related techniques that have garnered international attention, with Dr. Lin serving as a primary author.
Game-Changer in Malignant Brain Tumor Treatment: New Drug Extends Survival by Two Years
A breakthrough in brain tumor treatment has emerged! EverFront Biotech recently proposed a novel approach to cancer therapy and innovative treatments for brain tumors. The research focuses on the anti-cancer effects of BP, a small molecule compound. In experimental studies using rats, the targeted drug was delivered to the tumor site using small-molecule technology, ensuring stable drug release. Rats receiving a single treatment demonstrated an average survival time twice as long as those treated with conventional therapies. Founder of EverFront Biotech, Mr. Ho-Jin Chen, stated that this groundbreaking small-molecule cancer drug will be presented at three prestigious international conferences, marking a new milestone in Taiwan’s pharmaceutical research and development. In addition to the brain tumor therapy, EverFront Biotech is also engaged in developing a drug for the treatment of Amyotrophic Lateral Sclerosis (ALS), and promising results have been obtained in their research on ALS, with a patent application currently in progress.